Issuing stock is way of life for some small-cap biotech companies looking to raise cash. However, these three in particular are notorious for diluting shareholder value.
All three of these small-cap biotech stocks could return 200% (or more) for their shareholders if Wall Street's price targets are accurate.
Representing a true David versus Goliath battle in the biotech space, this $500 million cancer drug developer could soon dethrone a $21 billion giant.
Little-known Peregrine Pharmaceuticals reports solid revenue growth and pipeline achievements in its first-quarter report -- but is this small-cap cancer immunotherapy developer really investment material?
Investors in Flexion Therapeutics and Tetraphase Pharmaceuticals found out the hard way what can happen if you put a majority of your eggs in one basket.
Orexigen Therapeutics suffers a double-whammy in August, and its shares lose more than 30% of their value as a result. Is now the time to consider Orexigen a bargain?
Arena Pharmaceuticals' shareholders got a reality check following the company's second-quarter earnings results.
Normally the one designing the attack systems, Kratos found itself under attack from skeptics in August after reporting mixed second-quarter earnings results.
Sometimes having first-in-class technology doesn't guarantee success.
Interest is starting to heat up in the cancer immunotherapy space, and small-cap biotech Peregrine Pharmaceuticals finds itself squarely at ground zero.